Armata Pharmaceuticals, Inc. — Capital/Financing Update 2004

Feb 3, 2004

8-K 1 targeted8k_02022004.htm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2004 ___ Targeted Genetics Corporation (Exact name of registrant as specified in charter)

Washington	0-23930	91-1549568
(State or other
jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	1100 Olive Way, Suite 100 Seattle, Washington 98101
	(Address of principal
executive offices and Zip Code)
(206) 623-7612
	(Registrant's telephone
number, including area code)
Not Applicable (Former name or former address, if changed since
last report)

*********** MARKER PAGE="sheet: 4; page: 4"

Item 5. Other Events

MARKER FORMAT-SHEET="Para Indent" FSL="Default"

On February 2, 2004, Targeted Genetics Corporation announced a public offering of 10,854,247 shares of its common stock to institutional investors at a price of $2.35 per share, for gross proceeds of $25,507,504. The shares were offered under Targeted Genetics’ shelf registration statement on Form S-3 (File 333-107822), as amended.

MARKER FORMAT-SHEET="Para Indent" FSL="Default"

Targeted Genetics expects to receive net proceeds from the financing of approximately $23.8 million after deducting placement agent fees and estimated costs associated with the offering. SG Cowen Securities Corporation, or SG Cowen, and Roth Capital Partners, LLC, or Roth, served as placement agents for the transaction.

MARKER FORMAT-SHEET="Para Indent" FSL="Default"

Copies of the Placement Agent Agreement between Targeted Genetics and Roth, dated as of January 30, 2004 and the form of the Subscription Agreement among Targeted Genetics and each institutional purchaser, and the press release related to the offering are attached as Exhibits 1.1, 10.1 and 99.1 to this current report and are incorporated herein by reference.

Item 7. Financial Statements and Exhibits

MARKER FORMAT-SHEET="Para (List) Hang Level 1" FSL="Default"

(c) Exhibits.

MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default"

1.1 Placement Agent Agreement

MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default"

10.1 Form of Subscription Agreement

MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default"

99.1 Press Release of Targeted Genetics Corporation dated February 2, 2004

*********** MARKER PAGE="sheet: 1; page: 1"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Targeted Genetics Corporation
Date: February 3, 2004	By: /s/ Todd E. Simpson
	Todd E. Simpson Vice President, Finance and Administration,
Chief Financial Officer, Secretary and Treasurer

*********** MARKER PAGE="sheet: 3; page: 3"

EXHIBIT INDEX

MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default"

Exhibit Number Description

MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default"

1.1 Placement Agent Agreement

MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default"

10.1 Form of Subscription Agreement

MARKER FORMAT-SHEET="Para (List) Hang Level 2" FSL="Default"

99.1 Press Release of Targeted Genetics Corporation dated February 2, 2004

*********** MARKER PAGE="sheet: 2; page: 2"